Pathalys Pharma and Launch Therapeutics Announce First Patient Enrolled Ahead of Schedule in Pivotal Phase 3 Program for Upacicalcet in Patients Receiving Hemodialysis

Pathalys and LaunchTx leverage recently announced collaboration to accelerate enrollment for the upacicalcet development program. Research Triangle Park, North Carolina and Boston, Massachusetts, May 31, 2023 – Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and Launch Therapeutics (Launch Tx), a clinical development company, today announced that the first patient has …